Matinas BioPharma incurred a loss of $0.03 per share in 4Q, which met analysts’ expectations. The reported loss by the biopharmaceutical company was smaller than the prior-year quarter’s loss of $0.04 per share. Matinas’ (MTNB) research and development expenses increased 2.9% on a year-over-year basis to $3.5 million in the quarter, while total general and administrative expenses surged 30.4% to $3 million. Matinas CEO Jerome D. Jabbour said, “The completion of the head-to-head ENHANCE-IT trial of LYPDISO vs.